ForPatients
by Roche

HER2-positive Early Breast Cancer

A study to evaluate the use of a fixed-dose combination of pertuzumab and trastuzumab given as an injection under the skin for treating people with HER2-positive early breast cancer

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Country	2023-509321-50-00 ML42502

The clinical trial information herein is sourced from public registries such as ClinicalTrials.gov, EuClinicalTrials.eu, and ISRCTN.com. Additional patient-friendly (lay) content has been prepared by Roche to support understanding.

Official Title:

Trial Summary:

2023-509321-50-00 ML42502
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers

© 2022 F. Hoffmann-La Roche Ltd